LEGN (Legend Biotech) LT-Debt-to-Total-Asset : 0.20 (As of Sep. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Legend Biotech LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Legend Biotech's long-term debt to total assests ratio for the quarter that ended in Sep. 2024 was 0.20.

Legend Biotech's long-term debt to total assets ratio increased from Sep. 2023 (0.17) to Sep. 2024 (0.20). It may suggest that Legend Biotech is progressively becoming more dependent on debt to grow their business.

Legend Biotech LT-Debt-to-Total-Asset Historical Data

The historical data trend for Legend Biotech's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Legend Biotech LT-Debt-to-Total-Asset Chart

Legend Biotech Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.02

0.11

0.21

0.18

Legend Biotech Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.17	0.18	0.19	0.19	0.20

Legend Biotech LT-Debt-to-Total-Asset Calculation

Legend Biotech's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

LT Debt to Total Assets (A: Dec. 2023 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2023 )	/	Total Assets (A: Dec. 2023 )
	=	325.497	/	1848.609
	=	0.18

Legend Biotech's Long-Term Debt to Total Asset Ratio for the quarter that ended in Sep. 2024 is calculated as

LT Debt to Total Assets (Q: Sep. 2024 )	=	Long-Term Debt & Capital Lease Obligation (Q: Sep. 2024 )	/	Total Assets (Q: Sep. 2024 )
	=	342.249	/	1735.825
	=	0.20

Legend Biotech (NAS:LEGN) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Legend Biotech LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Legend Biotech's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Legend Biotech Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Legend Biotech Corp (NAS:LEGN) » Definitions » LT-Debt-to-Total-Asset

Comparable Companies

Traded in Other Exchanges

9LB:Germany

Address

2101 Cottontail Lane, Somerset, NJ, USA, 08873

Website

https://www.legendbiotech.com

Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's lead product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.